Unipolar Depression Clinical Trial
Official title:
Effects of Electroconvulsive Therapy on Serotonin-1A Receptor Binding in Major Depression
In treatment-resistant depression, electroconvulsive therapy (ECT) has been shown to
effectively reduce depressive symptoms, though the underlying neurobiological mechanism is
still unclear. The serotonergic system, and in particular the inhibitory serotonin-1A
(5-HT1A) receptor, appears to be significantly involved in the effectiveness of ECT. The aim
of the study is to assess the effects of ECT on the 5-HT1A receptor binding potential (BPND)
and distribution in humans in vivo using positron emission tomography (PET) and the
radioligand [carbonyl-11C]WAY-100635.
12 patients suffering from severe, therapy-resistant unipolar depression will undergo 3 PET
scans, two of these scans taking place before the ECT treatment, consisting of 6-14 ECTs,
the third scan taking place after the ECT treatment.
This imaging study hypothesizes that upon completion of the ECT, the overall 5-HT1A receptor
BPND in the brain of depressed patients will significantly change.
This study would be the first to demonstrate an effect of electroconvulsive therapy on the
5-HT1A receptor binding in humans in vivo. Given the involvement of the 5-HT1A receptor in
the pathophysiology of mood disorders, the present study would be an important step towards
a better understanding of antidepressant treatment and treatment response. By comparing
treatment effect and the underlying biological mechanism, the study might help to identify
biomarkers that distinguish patients who are likely to benefit from ECT from patients who
will rather be non-responders. Finally, by investigating the role of the 5-HT1A receptor in
ECT, is highly discussed relevance for antidepressant action will be further elucidated and
might prepare the ground for new therapeutic strategies.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03256162 -
Ketamine as an Adjunctive Therapy for Major Depression
|
Phase 1 | |
| Recruiting |
NCT05570110 -
Enoxolone in Major Depression - Biomarker-outcome Relationship
|
Phase 1/Phase 2 | |
| Completed |
NCT02530164 -
Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression
|
N/A | |
| Completed |
NCT00964054 -
Depression Outcomes Study of Exercise
|
Phase 1 | |
| Completed |
NCT01447602 -
A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior
|
Phase 3 | |
| Completed |
NCT00517387 -
The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression
|
Phase 3 | |
| Recruiting |
NCT04939649 -
Ketamine as an Adjunctive Therapy for Major Depression (2)
|
Phase 3 | |
| Recruiting |
NCT05894980 -
How to Reduce Suicidal Thoughts and Impulsivity in Depression
|
N/A | |
| Terminated |
NCT04712968 -
Efficacy of Daylight as Adjunctive Treatment in Patients With Depression
|
N/A | |
| Enrolling by invitation |
NCT04717921 -
Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
|
||
| Recruiting |
NCT03358056 -
Effects of Mindfulness Based Cognitive Therapy on Emotional Processing
|
N/A | |
| Recruiting |
NCT03711019 -
Efficacy of Convulsive Therapies During Continuation
|
N/A | |
| Completed |
NCT02104232 -
Thinking Healthy Program - Peer Delivered, India (THPP-I)
|
N/A | |
| Completed |
NCT02111915 -
Thinking Healthy Program - Peer Delivered (Pakistan)
|
N/A | |
| Terminated |
NCT01219686 -
EScitalopram PIndolol ONset of Action
|
Phase 2/Phase 3 | |
| Completed |
NCT00158990 -
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
|
Phase 3 | |
| Completed |
NCT01049347 -
Amitriptyline and Paroxetine Treatment of Major Depression
|
Phase 3 | |
| Completed |
NCT03268434 -
Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care
|
N/A | |
| Completed |
NCT01880957 -
PET and MRI Brain Imaging of Bipolar Disorder
|
N/A | |
| Completed |
NCT04420793 -
Voice Changes During ECT
|